Pfizer: positive results for a growth hormone

(CercleFinance.com) - Pfizer and Opko have announced positive results for a Phase III study for Somatrogon, a long-acting human growth hormone to treat children with growth hormone deficiency.


The study showed non-inferiority of this candidate drug in a weekly dose in pre-pubertal children, compared with somatropin in a daily dose, in terms of the growth rate after 12 months of treatment, thus reaching its primary endpoint.

For the record, both groups concluded a somatrogon agreement in 2014, under which Opko is responsible for conducting the clinical program and Pfizer, the drug's registering and marketing.


Copyright (c) 2019 CercleFinance.com. All rights reserved.